Revenue and net profit grew year-over-year for the quarter ended September 30, 2024, with strong cash flow and a robust balance sheet. The financials were reviewed and approved without qualifications, and the company remains focused on its pharmaceuticals segment.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.